Contents

Search

tripelennamine (PBZ, Pyribenzamine, Pyrinamine, Stanzamine)

Tradename: PBZ. (tripelennamine hydrochloride or citrate) Indications: - perenial or seasonal allergies - allergic rhinitis, allergic conjunctivitis - nasal congestion, cough, sneezing, rhinorrhea - other allergic conditions - urticaria, pruritus [3] Contraindications: 1) narrow-angle glaucoma 2) bladder neck obstruction 3) symptomatic prostatic hypertrophy 4) stenosing peptic ulcer Dosage: 1) adults a) 25-50 mg PO every 4-6 hours b) maximum 600 mg/day c) extended release: 100 mg BID-TID 2) infants & children a) 5 mg/kg/day in 4-6 divided doses b) maximum: 300 mg/day Tabs: 50 mg. Extended release: 100 mg. Adverse effects: 1) common (> 10%) - drowsiness (slight to moderate) - thickening of bronchial secretions 2) less common (1-10%) - headache, fatigue, increased appetite, increased weight, nervousness, dizziness, nausea, diarrhea, abdominal pain, dry mouth, pharyngitis, arthralgia 3) uncommon (< 1%) - angioedema, bronchospasm, depression, edema, epistaxis, hepatitis, myalgia, palpitations, paresthesias, photosensitivity, rash, hypotension, sedation, paradoxical excitement, insomnia, tremor, blurred vision, urinary retention Laboratory: 1) specimen: serum 2) methods: GLC 3) labs with Loincs - tripelennamine in blood - tripelennamine in gastric fluid - tripelennamine in serum/plasma - tripelennamine in serum/plasma/urine - tripelennamine in urine

Interactions

drug adverse effects of H1 receptor antagonists

General

ethylenediamine H1 receptor antagonist (antihistamine)

Properties

MISC-INFO: therapeutic-range 20-60 NG/ML toxic-range >0.5 UG/ML >1.96 UMOL/L

Database Correlations

PUBCHEM correlations

References

  1. Kaiser Permanente Northern California Regional Drug Formulary, 1998
  2. Clinical Guide to Laboratory Tests, 3rd ed. Teitz ed., W.B. Saunders, 1995
  3. Deprecated Reference

Component-of

diphenhydramine/tripelennamine